ERBB2 and breast cancer: The phase III PALOMA-3 study (Turner et al., 2015) enrolled women (pre- or postmenopausal) with ER-positive, HER2-negative advanced breast cancer that had relapsed or progressed on prior HT (about 25% had received prior HT only for early-stage disease).